Forskning ved Københavns Universitet - Københavns Universitet

Forside

Immunogenicity of Bcl-2 in patients with cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Immunogenicity of Bcl-2 in patients with cancer. / Andersen, Mads Hald; Svane, Inge Marie; Kvistborg, Pia; Nielsen, Ove Juul; Balslev, Eva; Reker, Sine; Becker, Jürgen C; Straten, Per Thor.

I: Blood, Bind 105, Nr. 2, 15.01.2005, s. 728-34.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Andersen, MH, Svane, IM, Kvistborg, P, Nielsen, OJ, Balslev, E, Reker, S, Becker, JC & Straten, PT 2005, 'Immunogenicity of Bcl-2 in patients with cancer', Blood, bind 105, nr. 2, s. 728-34. https://doi.org/10.1182/blood-2004-07-2548

APA

Andersen, M. H., Svane, I. M., Kvistborg, P., Nielsen, O. J., Balslev, E., Reker, S., Becker, J. C., & Straten, P. T. (2005). Immunogenicity of Bcl-2 in patients with cancer. Blood, 105(2), 728-34. https://doi.org/10.1182/blood-2004-07-2548

Vancouver

Andersen MH, Svane IM, Kvistborg P, Nielsen OJ, Balslev E, Reker S o.a. Immunogenicity of Bcl-2 in patients with cancer. Blood. 2005 jan 15;105(2):728-34. https://doi.org/10.1182/blood-2004-07-2548

Author

Andersen, Mads Hald ; Svane, Inge Marie ; Kvistborg, Pia ; Nielsen, Ove Juul ; Balslev, Eva ; Reker, Sine ; Becker, Jürgen C ; Straten, Per Thor. / Immunogenicity of Bcl-2 in patients with cancer. I: Blood. 2005 ; Bind 105, Nr. 2. s. 728-34.

Bibtex

@article{4d73a4c24bce40008b382bf7a2d632b4,
title = "Immunogenicity of Bcl-2 in patients with cancer",
abstract = "B-cell lymphoma 2 (Bcl-2) is a pivotal regulator of apoptotic cell death and it is overexpressed in many cancers. Consequently, the Bcl-2 protein is an attractive target for drug design, and Bcl-2-specific antisense oligonucleotides or small-molecule Bcl-2 inhibitors have shown broad anticancer activities in preclinical models and are currently in several clinical trials. The clinical application of immunotherapy against cancer is rapidly moving forward in multiple areas, including the adoptive transfer of anti-tumor-reactive T cells and the use of {"}therapeutic{"} vaccines. The overexpression of Bcl-2 in cancer and the fact that immune escape by down-regulation or loss of expression of this protein would impair sustained tumor growth makes Bcl-2 a very attractive target for anticancer immunotherapy. Herein, we describe spontaneous T-cell reactivity against Bcl-2 in peripheral blood from patients suffering from unrelated tumor types (ie, pancreatic cancer, breast cancer, acute myeloid leukemia [AML], and chronic lymphocytic leukemia [CLL]). Additionally, we show that these Bcl-2-reactive T cells are indeed peptide-specific, cytotoxic effector cells. Thus, Bcl-2 may serve as an important and widely applicable target for anticancer immunotherapeutic strategies (eg, in the combination with conventional radiotherapy and chemotherapy).",
author = "Andersen, {Mads Hald} and Svane, {Inge Marie} and Pia Kvistborg and Nielsen, {Ove Juul} and Eva Balslev and Sine Reker and Becker, {J{\"u}rgen C} and Straten, {Per Thor}",
year = "2005",
month = jan,
day = "15",
doi = "http://dx.doi.org/10.1182/blood-2004-07-2548",
language = "English",
volume = "105",
pages = "728--34",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

RIS

TY - JOUR

T1 - Immunogenicity of Bcl-2 in patients with cancer

AU - Andersen, Mads Hald

AU - Svane, Inge Marie

AU - Kvistborg, Pia

AU - Nielsen, Ove Juul

AU - Balslev, Eva

AU - Reker, Sine

AU - Becker, Jürgen C

AU - Straten, Per Thor

PY - 2005/1/15

Y1 - 2005/1/15

N2 - B-cell lymphoma 2 (Bcl-2) is a pivotal regulator of apoptotic cell death and it is overexpressed in many cancers. Consequently, the Bcl-2 protein is an attractive target for drug design, and Bcl-2-specific antisense oligonucleotides or small-molecule Bcl-2 inhibitors have shown broad anticancer activities in preclinical models and are currently in several clinical trials. The clinical application of immunotherapy against cancer is rapidly moving forward in multiple areas, including the adoptive transfer of anti-tumor-reactive T cells and the use of "therapeutic" vaccines. The overexpression of Bcl-2 in cancer and the fact that immune escape by down-regulation or loss of expression of this protein would impair sustained tumor growth makes Bcl-2 a very attractive target for anticancer immunotherapy. Herein, we describe spontaneous T-cell reactivity against Bcl-2 in peripheral blood from patients suffering from unrelated tumor types (ie, pancreatic cancer, breast cancer, acute myeloid leukemia [AML], and chronic lymphocytic leukemia [CLL]). Additionally, we show that these Bcl-2-reactive T cells are indeed peptide-specific, cytotoxic effector cells. Thus, Bcl-2 may serve as an important and widely applicable target for anticancer immunotherapeutic strategies (eg, in the combination with conventional radiotherapy and chemotherapy).

AB - B-cell lymphoma 2 (Bcl-2) is a pivotal regulator of apoptotic cell death and it is overexpressed in many cancers. Consequently, the Bcl-2 protein is an attractive target for drug design, and Bcl-2-specific antisense oligonucleotides or small-molecule Bcl-2 inhibitors have shown broad anticancer activities in preclinical models and are currently in several clinical trials. The clinical application of immunotherapy against cancer is rapidly moving forward in multiple areas, including the adoptive transfer of anti-tumor-reactive T cells and the use of "therapeutic" vaccines. The overexpression of Bcl-2 in cancer and the fact that immune escape by down-regulation or loss of expression of this protein would impair sustained tumor growth makes Bcl-2 a very attractive target for anticancer immunotherapy. Herein, we describe spontaneous T-cell reactivity against Bcl-2 in peripheral blood from patients suffering from unrelated tumor types (ie, pancreatic cancer, breast cancer, acute myeloid leukemia [AML], and chronic lymphocytic leukemia [CLL]). Additionally, we show that these Bcl-2-reactive T cells are indeed peptide-specific, cytotoxic effector cells. Thus, Bcl-2 may serve as an important and widely applicable target for anticancer immunotherapeutic strategies (eg, in the combination with conventional radiotherapy and chemotherapy).

U2 - http://dx.doi.org/10.1182/blood-2004-07-2548

DO - http://dx.doi.org/10.1182/blood-2004-07-2548

M3 - Journal article

VL - 105

SP - 728

EP - 734

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -

ID: 48579669